Episode 15 – Minimise variability issues in your organoids
Join our experts as they discuss factors causing variability issues in organoids and how to avoid them.
List view / Grid view
Join our experts as they discuss factors causing variability issues in organoids and how to avoid them.
This supplement focuses on how cell and gene therapy can target diseases such as cancer and reduce elevated lipoprotein(a).
CIRM grant will fund novel gene therapy that aims for single lifelong treatment of Friedreich’s ataxia, a progressive neuromuscular disorder; a second CIRM grant will advance efforts to leverage UC San Diego research on another rare disease
This ebook details Euretos’ approach to predicting novel gene-disease associations including a case study on Multiple Sclerosis GWAS and drug targets.
Imaging the structure and function of the nervous system at a cellular level – challenges and considerations.
In primate models, researchers have successfully shown that developed AAVs can cross the blood-brain barrier, which keeps many drugs from getting into the brain.
Researchers have identified a protein that, when present in high amounts in breast cancer tumours, is an indicator of whether DNA-damaging therapies will work or not.
Dr. Stokes, Associate Director Proteomics, discusses how proteomic studies can increase effectiveness, speed of target and biomarker identification.
Japanese researchers found an ASD-like behavioural impairment in chicks, suggesting a molecular pathway of ASD pathogenesis.
US researchers have identified a protein that interacts and enhances the spread of neurotoxic species of tau, which is primarily found in neurons that appear abnormal in the brains of Alzheimer’s disease patients.
Sloan Kettering Institute (SKI) researchers have developed a new machete technique to slice into the cancer genome and study copy number alterations.
Drug Target Review’s Ria Kakkad recently travelled to Barcelona to attend PEGS Europe’s Protein and Antibody Engineering Summit. In this article, she shares her highlights from the event.
US researchers have uncovered the uncapped potential that gut-friendly bacteria has for improving treatments of inflammatory bowel disease (IBD).
In this article, Drug Target Review’s Ria Kakkad shares some of the most recent progress in discovering a drug for COPD, a disease that remains a major challenge in the medical industry.
The study, involving mice, found that the neurotransmitter can act as a break to dopamine.